Menopausal support (energy, mood, muscle retention): creatine is a woman’s powerful ally during the menopause face as it ...

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be ...

Natural Chromium Picolinate- this ingredient helps you control hunger and food cravings. Additionally, it makes your system ...

Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Skye, or following a bona fide period of non-employment, as an inducement ...

In January 2025, Elicio reached alignment with regulatory authorities on a registrational strategy for ELI-002 in post-resection (adjuvant setting) mKRAS PDAC. Specifically, Elicio aligned with the ...

MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported ...

OLPRUVA: 5 new patient enrollment forms were received in Q1 2025, bringing the total from initial product availability in July 2023, and including Zevra's promotion of OLPRUVA since late January 2024, ...

Verrica recognized product revenue of $3.4 million in the first quarter of 2025, which relates to the delivery of YCANTH (VP-102) to its distribution partners.

Total Operating Expenses: Total operating expenses were $42.9 million for the first quarter of 2025, including research and development expenses of $29.1 million and general and administrative ...

Research and development expenses were $15.3 million for the third quarter of fiscal 2025, compared with $12.4 million for the same period a year ago, with the increase primarily attributable to ...

MOUNTAIN VIEW, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and ...

Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities ...